Zebra Capital Management’s Denali Therapeutics DNLI Stock Holding History

Zebra Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,495	Closed	-$200K	–	130
2021 Q4	$200K	Sell	4,495 -1,657	-27%	-$78.5K	0.32%	120
2021 Q3	$310K	Sell	6,152 -1,891	-24%	-$107K	0.38%	100
2021 Q2	$631K	Sell	8,043 -869	-10%	-$53.8K	0.74%	48
2021 Q1	$509K	Buy	+8,912	New	+$597K	0.56%	66
2020 Q3	–	Sell	-9,089	Closed	-$220K	–	194
2020 Q2	$220K	Buy	+9,089	New	+$214K	0.32%	135

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Zebra Capital Management's DNLI Position: Q1 2022 in Review

Zebra Capital Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 4,495 shares — an estimated $200K sold.

Zebra Capital Management first reported a position in DNLI in Q2 2020 and held it in 5 quarters. The position peaked at $631K in Q2 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

Zebra Capital Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
Zebra Capital Management sold 4,495 Denali Therapeutics shares in Q1 2022, an estimated $200K.
Zebra Capital Management first reported a position in Denali Therapeutics in Q2 2020 and held it in 5 quarters.
Zebra Capital Management's Denali Therapeutics position peaked at $631K in Q2 2021.
190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Zebra Capital Management's 13F filing for Q1 2022, filed 16 May 2022.